Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 741

1.

Visuo-spatial construction trajectories in Fragile X Syndrome (FXS) and Autism Spectrum Disorders (ASD): Evidence of cognitive heterogeneity within neurodevelopmental conditions.

Ballantyne CJ, Núñez M, Manoussaki K.

Res Dev Disabil. 2017 Sep 15;70:113-125. doi: 10.1016/j.ridd.2017.08.005. [Epub ahead of print]

PMID:
28923376
2.

Association of midlife lipids with 20-year cognitive change: A cohort study.

Power MC, Rawlings A, Sharrett AR, Bandeen-Roche K, Coresh J, Ballantyne CM, Pokharel Y, Michos ED, Penman A, Alonso A, Knopman D, Mosley TH, Gottesman RF.

Alzheimers Dement. 2017 Sep 12. pii: S1552-5260(17)33691-9. doi: 10.1016/j.jalz.2017.07.757. [Epub ahead of print]

PMID:
28916238
3.

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr.

J Am Coll Cardiol. 2017 Aug 30. pii: S0735-1097(17)38898-8. doi: 10.1016/j.jacc.2017.07.745. [Epub ahead of print]

PMID:
28886926
4.

Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.

Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, McEvoy JW, Grams ME, Coresh J.

Kidney Int. 2017 Aug 30. pii: S0085-2538(17)30497-0. doi: 10.1016/j.kint.2017.06.028. [Epub ahead of print]

PMID:
28865675
5.

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group.

Lancet. 2017 Aug 25. pii: S0140-6736(17)32247-X. doi: 10.1016/S0140-6736(17)32247-X. [Epub ahead of print]

PMID:
28855077
6.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group.

N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

7.

Cognitive Function in a Randomized Trial of Evolocumab.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators.

N Engl J Med. 2017 Aug 17;377(7):633-643. doi: 10.1056/NEJMoa1701131.

PMID:
28813214
8.

Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study.

van Capelleveen JC, Bochem AE, Boekholdt SM, Mora S, Hoogeveen RC, Ballantyne CM, Ridker PM, Sun W, Barter PJ, Tall AR, Zwinderman AH, Kastelein JJP, Wareham NJ, Khaw KT, Hovingh GK.

J Am Heart Assoc. 2017 Aug 3;6(8). pii: e006636. doi: 10.1161/JAHA.117.006636.

9.

Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.

Puri R, Ballantyne CM, Hoogeveen RC, Shao M, Barter P, Libby P, Chapman MJ, Erbel R, Arsenault BJ, Raichlen JS, Nissen SE, Nicholls SJ.

Atherosclerosis. 2017 Aug;263:137-144. doi: 10.1016/j.atherosclerosis.2017.06.026. Epub 2017 Jun 15.

PMID:
28641153
10.

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

Ballantyne CM, Shah S, Sapre A, Ashraf TB, Tobias SC, Sahin T, Ye P, Dong Y, Sheu WH, Kang DH, Ferreira Rossi PR, Moiseeva Y, Briones IR, Johnson-Levonas AO, Mitchel YB.

Am J Cardiol. 2017 Aug 15;120(4):569-576. doi: 10.1016/j.amjcard.2017.03.255. Epub 2017 Apr 12.

11.

Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative.

Lo GH, McAlindon TE, Katz JN, Driban JB, Price LL, Eaton CB, Petersen NJ, Ballantyne CM, Suarez-Almazor ME.

Clin Rheumatol. 2017 Jun 1. doi: 10.1007/s10067-017-3656-z. [Epub ahead of print]

PMID:
28573369
12.

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hoefer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium, Krämer BK, Scharnagl H, Fliser D, März W, Speer T.

Lancet Diabetes Endocrinol. 2017 Jul;5(7):534-543. doi: 10.1016/S2213-8587(17)30096-7. Epub 2017 May 26.

PMID:
28566218
13.

The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.

Agarwala A, Pokharel Y, Saeed A, Sun W, Virani SS, Nambi V, Ndumele C, Shahar E, Heiss G, Boerwinkle E, Konety S, Hoogeveen RC, Ballantyne CM.

Atherosclerosis. 2017 Jul;262:131-137. doi: 10.1016/j.atherosclerosis.2017.05.014. Epub 2017 May 12.

PMID:
28554015
14.

Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study.

Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED.

Nutrition. 2017 Jun;38:85-93. doi: 10.1016/j.nut.2017.01.008. Epub 2017 Feb 3.

PMID:
28526388
15.

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators.

N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581.

PMID:
28514624
16.

A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.

Saeed A, Virani SS, Jones PH, Nambi V, Zoch D, Ballantyne CM.

J Clin Lipidol. 2017 May - Jun;11(3):596-599. doi: 10.1016/j.jacl.2017.02.015. Epub 2017 Mar 9. No abstract available.

PMID:
28506382
17.

The Upregulation of Integrin αDβ2 (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis.

Aziz MH, Cui K, Das M, Brown KE, Ardell CL, Febbraio M, Pluskota E, Han J, Wu H, Ballantyne CM, Smith JD, Cathcart MK, Yakubenko VP.

J Immunol. 2017 Jun 15;198(12):4855-4867. doi: 10.4049/jimmunol.1602175. Epub 2017 May 12.

PMID:
28500072
18.

Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia.

Wu H, Ballantyne CM.

Nat Rev Cardiol. 2017 Jul;14(7):385-386. doi: 10.1038/nrcardio.2017.75. Epub 2017 May 11. No abstract available.

PMID:
28492287
19.

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs.

Virani SS, Akeroyd JM, Nambi V, Heidenreich PA, Morris PB, Nasir K, Michos ED, Bittner VA, Petersen LA, Ballantyne CM.

Circulation. 2017 Jun 20;135(25):2572-2574. doi: 10.1161/CIRCULATIONAHA.117.028503. Epub 2017 May 2. No abstract available.

PMID:
28465286
20.

Physical Activity, Obesity, and Subclinical Myocardial Damage.

Florido R, Ndumele CE, Kwak L, Pang Y, Matsushita K, Schrack JA, Lazo M, Nambi V, Blumenthal RS, Folsom AR, Coresh J, Ballantyne CM, Selvin E.

JACC Heart Fail. 2017 May;5(5):377-384. doi: 10.1016/j.jchf.2017.02.002.

PMID:
28449797

Supplemental Content

Loading ...
Support Center